Portfolio Company News Why ex-Dendreon CEO’s New Startup Could Succeed As former CEO of Seattle biotech DendreonCorp. Mitchell Gold embarks on a new biotech immunotherapy…adminApril 17, 2015
Portfolio Company News Former Dendreon CEO Launches Stealth Next-gen Immunotherapy Startup in Seattle He’s launching a next-generation immunotherapy startup called Alpine Immune Sciences, seeding about $1.3 million into the company…adminFebruary 1, 2015
Portfolio Company News Seattle Biotech Oncothyreon Pays $27 million for Alpine Biosciences Seattle biotechnology company Oncothyreon has acquired another local firm, Alpine Biosciences, for about $27 million…adminAugust 17, 2014
Portfolio Company News A “Revolution”: Oncothyreon CEO on Alpine Biosciences Acquisition Seattle-based oncology company Oncothyreon Inc. has acquired Alpine Biosciences, a Seattle-based biotechnology company developing what are…adminAugust 17, 2014
Portfolio Company News Oncothyreon Announces Acquisition of Alpine Biosciences Oncothyreon to Leverage Alpine's Protocell Technology to Enable Targeted Delivery of Molecular Therapeutics for Serious…adminAugust 2, 2014
Portfolio Company News UNM’s Protocell Technology Attracts Successful Entrepreneur, Investor, and Pioneer in Emerging Cancer Therapies A joint technology developed at the University of New Mexico and Sandia National Labs that…adminDecember 13, 2013
Portfolio Company News Protocell Cancer Therapy Gains Potent Backer Dr. Mitchell H. Gold, a nationally recognized pioneer in emerging cancer-fighting therapies, is throwing his…adminDecember 9, 2013